Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application.

Gastroenterol Res Pract · 2016 · PMC4736909 · PMID 26880889

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The proportion of advanced gastric cancer in all enrolled patients was 85/147; at the endpoint, regorafenib group got significantly longer median PFS than placebo group (11 weeks versus 3.9 weeks, P < 0.0001) and the median OS (25 weeks versus 19.4 weeks, P = 0.11) also showed a positive trend [ 29 ].

also in 6,846 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.